The Recall Desk
SevereFDA (Drugs)·D-1055-2014·Announced 2014-02-12

Fusion Pharmaceuticals Recalls Dicopanol FusePaq Kits Due to Yeast Contamination

Fusion Pharmaceuticals is recalling Dicopanol FusePaq Kits for Oral Suspension because they contain yeast and mold levels above USP limits.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The agency classified this as an FDA Class II recall. Per the rubric, FDA Class II recalls with potential for adverse health consequences are classified as Severe (Score 4).

Plain-English summary

Fusion Pharmaceuticals, LLC is recalling 1,200 kits of Dicopanol FusePaq Kit for Oral Suspension, 5mg/ML. The recall affects lots PL520, PL521, PL522, and PL523, which were distributed in California.

The recall was initiated because the product was found to have Total Yeasts and Molds Counts above the limits established by the United States Pharmacopeia (USP). This is a Class II recall, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.

Consumers who have these specific lots of Dicopanol FusePaq Kits should stop using them and contact their healthcare provider or the recalling firm for instructions on how to return or dispose of the product.

The recalled product

Product
Dicopanol FusePaq Kit for Oral Suspension, 5mg/ML
Affected units
1,200

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (3)

  • Lots: PL520
  • PL521
  • PL522 and PL523

Distribution

Distributed in 1 state:

Same manufacturer · Fusion Pharmaceuticals, LLC

See all →